Abstract
Purpose: We evaluated the erectogenic properties of a new cyclic α-melanocyte-stimulating hormone analogue, Melanotan-II, to treat men with psychogenic erectile dysfunction. Materials and Methods: Ten men with erectile dysfunction of no known organic cause were entered in a double-blind, placebo controlled crossover study in which the erectogenic properties of Melanotan- II and a vehicle placebo were compared using real-time RigiScan monitoring. The presence, duration and rigidity of erections were recorded during a 6-hour period. Results: In 8 of 10 men treated with Melanotan-II clinically apparent erections developed. Mean duration of tip rigidity greater than 80% was 38.0 minutes with Melanotan-II and 3.0 with placebo (p = 0.0045). Transient side effects of nausea, stretching and yawning, and decreased appetite were reported more frequently after injections of Melanotan-II than placebo but none required treatment. Conclusions: Melanotan- II is a potent initiator of erections in men with psychogenic erectile dysfunction and has manageable side effects at a dose of 0.025 mg./kg.
Original language | English (US) |
---|---|
Pages (from-to) | 389-393 |
Number of pages | 5 |
Journal | Journal of Urology |
Volume | 160 |
Issue number | 2 |
DOIs | |
State | Published - Aug 1998 |
Externally published | Yes |
Keywords
- MSH
- Penile erection
ASJC Scopus subject areas
- Urology